Genetics and outcome of atypical hemolytic uremic syndrome: A nationwide French series comparing children and adults, Clin J Am Soc Nephrol, vol.8, pp.554-562, 2013. ,
Frémeaux-Bacchi V: Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: An analysis of 19 cases, Am J Kidney Dis, vol.63, pp.40-48, 2014. ,
Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype, Clin J Am Soc Nephrol, vol.5, pp.1844-1859, 2010. ,
Eculizumab in atypical hemolyticuremic syndrome, N Engl J Med, vol.369, pp.1379-1380, 2013. ,
Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies, Kidney Int, vol.87, pp.1061-1073, 2015. ,
Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: A single-arm, openlabel trial, Am J Kidney Dis, vol.68, pp.84-93, 2016. ,
An international consensus approach to the management of atypical hemolytic uremic syndrome in children, Pediatr Nephrol, vol.31, pp.15-39, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-02149335
Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome, Kidney Int, vol.89, pp.701-711, 2016. ,
Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS, Blood, vol.125, pp.3253-3262, 2015. ,
Dynamics of complement activation in aHUS and how to monitor eculizumab therapy, Blood, vol.124, pp.1715-1726, 2014. ,
Modification of Diet in Renal Disease Study Group: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation, Ann Intern Med, vol.130, pp.461-470, 1999. ,
New equations to estimate GFR in children with CKD, J Am Soc Nephrol, vol.20, pp.629-637, 2009. ,
Defining the genetics of thrombotic microangiopathies, Transfus Apheresis Sci, vol.54, pp.212-219, 2016. ,
FremeauxBacchi V: Mutations in components of complement influence the outcome of factor I-associated atypical hemolytic uremic syndrome, Kidney Int, vol.77, pp.339-349, 2010. ,
Rare genetic variants in the CFI gene are associated with advanced age-related macular degeneration and commonly result in reduced serum factor I levels, Hum Mol Genet, vol.24, pp.3861-3870, 2015. ,
Disturbed sialic acid recognition on endothelial cells and platelets in complement attack causes atypical hemolytic uremic syndrome, Blood, vol.127, pp.2701-2710, 2016. ,
Rodríguez de Có rdoba S: Molecular basis of factor H R1210C association with ocular and renal diseases, J Am Soc Nephrol, vol.27, pp.1305-1311, 2016. ,
Atypical haemolytic uraemic syndrome associated with a hybrid complement gene, J Immunol Methods, vol.3, pp.8-26, 2011. ,
Fremeaux-Bacchi V: Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome, Blood, vol.125, pp.2359-2369, 2015. ,
Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: A report of 10 cases, Am J Kidney Dis, vol.64, pp.633-637, 2014. ,
Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: An update, Am J Kidney Dis, vol.66, pp.172-173, 2015. ,
A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience, QJM, vol.109, pp.27-33, 2016. ,
Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome, Am J Kidney Dis, vol.65, 2015. ,
,
, French Study Group for aHUS/C3G: Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies, Nat Rev Nephrol, vol.8, pp.643-657, 2012.